Social Leverage Letter | Issue #15

$50M Series B for Robin Healthcare, The Future of Work; Remote or Hybrid? and Jobs

The Social Leverage Letter is a weekly newsletter for early-stage seed startups and investors. Receive it directly in your inbox every Sunday. Subscribe now.

UPFRONT

We're excited to announce the $50 million Series B raise for Fund III company, Robin Healthcare.

Fund III company 1upHealth is in the news. Congratulations on being named "Most Innovative Digital Health Startup" by CB Insights.

READING

COVID has fundamentally shifted the way we work. Recruiting is often cited as a top, if not the top, concern for startups. Understanding the nature of how the workforce is changing post-COVID isn't a luxury for founders; it's a necessity. 

WATCHING

YouTube | Founder in Focus

Social Leverage managing partner Gary Benitt recently sat down with Robin Healthcare (Fund III) CEO Emilio Galan to discuss how the company is looking to fundamentally fix the US healthcare system. Emilio has taken on the challenge of bringing together data, devices, and software, in an industry that is incredibly resistant to change.

JOB BOARD

We're Hiring! — Social Leverage:

Current openings at Social Leverage portfolio companies:

Our portfolio companies are seeking great candidates to fill roles in engineering, product management, design, sales, marketing, HR, and more. Browse ALL available opportunities here.

Check out all of our portfolio companies at Social Leverage.

© 2017-2021 All Rights Reserved, Social Leverage LLC.

Affiliate Disclosure: Social Leverage Group, LLC ("SLG"), Social Leverage Capital Fund I, LP ("SLC"), Social Leverage Capital Fund II, LP ("SLCII"), Social Leverage Capital Fund III, LP ("SLCIII") and Social Leverage Capital Fund IV, LP ("SLCIV") are all distinct entities from Social Leverage, LLC ("SL"). Social Leverage is not a registered investment advisor. SLC, SLCII, SLCIII, SLCIV, SLG and SL have used the logo and branding of Social Leverage with the permission of Social Leverage Group, LLC.